TITLE

The Roles of Bone Mineral Density, Bone Turnover, and Other Properties in Reducing Fracture Risk During Antiresorptive Therapy

AUTHOR(S)
Epstein, Solomon
PUB. DATE
March 2005
SOURCE
Mayo Clinic Proceedings;Mar2005, Vol. 80 Issue 3, p379
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Osteoporosis is a skeletal disorder characterized by compromised bone strength and increased risk of fracture. Properties related to bone strength include rate of bone turnover, bone mineral density, geometry, microarchitecture, and mean degree of mineralization. These properties (with or without bone density) are sometimes collectively referred to as bone quality. Antiresorptive agents may reduce fracture risk by several separate but interrelated effects on these individual properties. For example, antiresorptive agents have been reported to reduce bone turnover, stabilize or increase bone density, preserve or improve microarchitecture, reduce the number or size of resorption sites, and improve mineralization. Although changes in bone architecture and mineralization are not currently measurable in clinical practice, bone turnover is assessed easily in vivo and affects the other bone properties. Moreover, antiresorptive therapies that produce larger decreases in bone turnover markers together with larger Increases in bone mineral density are associated with greater reductions in fracture risk, especially at sites primarily composed of cortical bone such as the hip. Reductions in fracture risk are the most convincing evidence of good bone quality. Data from well-designed randomized clinical trials with up to 10 years of continuous antiresorptive therapy have shown that certain antiresorptive agents effectively reduce fracture risk and (together with extensive preclinical data) suggest no deleterious effects on bone quality.
ACCESSION #
16433852

 

Related Articles

  • Emerging therapies for the treatment of osteoporosis. Bhutani, Garima; Gupta, Mahesh Chander // Journal of Mid-life Health;Jul-Sep2013, Vol. 4 Issue 3, p147 

    Osteoporosis is a chronic disease of the osseous system characterized by decreased bone strength and increased fracture risk. It is due to an imbalance in the dynamic ongoing processes of bone formation and bone resorption. Currently available osteoporosis therapies like bisphosphonates,...

  • EDITORIAL. Rutkowski, James L. // Journal of Oral Implantology;2011, Vol. 37 Issue 5, p505 

    The author discusses the health effect of glucocorticosteriod (prednisone) therapy. He cites that glucocorticoid-induced osteoporosis (GIOP) is a common side of using steroid and it causes an increased risk of bone fractures, resorption and subsequent reduced formation. The guidelines issued by...

  • Design of Cathepsin K Inhibitors for Osteoporosis. Deaton, David N.; Tavares, Francis X. // Current Topics in Medicinal Chemistry;Nov2005, Vol. 5 Issue 16, p1639 

    Osteoporosis is a progressive, debilitating bone disease resulting in increased cost and morbidity to the elderly. This review summarizes the therapeutic approaches taken in the treatment of osteoporosis with particular emphasis on cathepsin K inhibitors. Cathepsin K, a cysteine protease...

  • bone resorption. Peters, Michael // BMA A-Z Family Medical Encyclopedia;2004, p116 

    An encyclopedia entry for "bone resorption" is presented. The term refers to the loss of bone tissue. It cites the association between bone resorption and the laying down of new bone tissue. Bone resorption, with increasing age, exceeds the formation of new bone, along with the gradual thinning...

  • Licochalcone A up-regulates of FasL in mesenchymal stem cells to strengthen bone formation and increase bone mass. Leiguo Ming; Fang Jin; Ping Huang; Hailang Luo; Wenjia Liu; Leilei Zhang; Wei Yuan; Yongjie Zhang; Yan Jin // Scientific Reports;11/28/2014, p1 

    The role of βone marrow-derived mesenchymal stem cells(BMSCs)in the pathogenesis and therapy of osteoporosis has drawn increasing attention in recent years. In the development of osteoporosis, it has βeen demonstrated that many changes occurred in the βehavior of BMSCs. For example, the...

  • NOT FOR WOMEN ONLY. Raisch, Molly // Prevention;Jun2012, Vol. 64 Issue 6, p40 

    The article reports that men also get osteoporosis but unlike women, bone loss is more gradual and the outlook for men after a fracture is reportedly worse than it is for women.

  • Osteoporosis facts.  // Geriatrics;Jul2000, Vol. 55 Issue 7, p23 

    Presents information on osteoporosis. Fractures resulting from osteoporosis; Exercises patients can perform to strengthen their bones and muscles.

  • THE BONE SCANDAL. Krucoff, Carol // Prevention;Jun2002, Vol. 54 Issue 6, p118 

    Contends that there is a the widespread failure of U.S. physicians to diagnose and treat osteoporosis after a fracture, despite availability of diagnostic tests and drugs to help prevent bone deterioration.

  • Development and validation of a population-based prediction scale for osteoporotic fracture in the region of Valencia, Spain: the ESOSVAL-R study. Sanfélix-Genovés, José; Peiró, Salvador; Sanfélix-Gimeno, Gabriel; Giner, Vicente; Gil, Vicente; Pascual, Manuel; Fluixá, Carlos; Fuertes, Antonio; Hurtado, Isabel; Ferreros, Inmaculada // BMC Public Health;2010, Vol. 10 Issue 1, p153 

    Background: Today, while there are effective drugs that reduce the risk of osteoporotic fracture, yet there are no broadly accepted criteria that can be used to estimate risks and decide who should receive treatment. One of the actual priorities of clinical research is to develop a set of simple...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics